High-level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma
High-level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma
复制标题
SETD1B 基因高水平表达与肝细胞癌的不良预后相关
DOI：
10.3892/mmr.2019.9832
复制
发表时间：
2019-03-01
影响因子：
3.4
通讯作者：
Yang, Penghui
中科院分区：
文献类型：
--
作者：
Chen, Dong;Li, Tieling;Yang, Penghui
SET结构域1B（SET domain containing 1B，SETD 1B）基因参与多种生物学过程，包括肿瘤的发生和发展。然而，SETD 1B在肝细胞癌（HCC）中的作用在很大程度上尚未探索。本研究检测了肝癌患者中SETD 1B的表达，并评估其临床意义。逆转录定量聚合酶链反应（RT-PCR）和蛋白质印迹（Western blot）分析结果显示，肝癌组织中SETD 1B mRNA和蛋白的表达水平均显著高于癌旁正常组织。此外，对患者临床因素的分析表明，增加的SETD 1B表达水平与肿瘤大小、临床分期和肝硬化相关。与SETD 1B表达水平升高的患者相比，SETD 1B表达水平降低的HCC患者的生存时间更长。此外，考克斯回归分析结果表明，SETD 1B的上调是HCC患者的独立预后标志物。综上所述，这些结果表明，SETD 1B在HCC的进展中是必不可少的，并且可以用作HCC的潜在预后标志物和治疗靶点。
The SET domain-containing 1B (SETD1B) gene is involved in multiple biological processes, including tumor development and progression. However, the role of SETD1B in hepatocellular carcinoma (HCC) is largely unexplored. The present study, examined the expression of SETD1B in patients with HCC and assessed its clinical significance. Reverse transcriptase quantitative polymerase chain reaction and western blot analysis results revealed that the expression levels of SETD1B mRNA and protein were significantly increased in HCC tumor tissues compared with the adjacent normal tissues. In addition, an analysis of the patient clinical factors indicated that increased levels of SETD1B expression were associated with tumor size, clinical stage and liver cirrhosis. Patients with HCC with decreased levels of SETD1B expression exhibited longer survival times compared with those with increased levels of SETD1B expression. In addition, Cox's regression analysis results implied that the upregulation of SETD1B was an independent prognostic marker in patients with HCC. Taken together, the results demonstrated that SETD1B is essential in the progression of HCC and may be used as a potential prognostic marker and therapeutic target in HCC.